Vildagliptin – now fully funded gliptin for type 2 diabetes

Goodfellow Gems Logo

Goodfellow Gems

Vildagliptin – now fully funded gliptin for type 2 diabetes

Vildagliptin, a DPP-4 class of medication, is now fully funded in NZ for type 2 diabetes. It is recommended as a second or third line oral anti-hyperglycaemic, added to metformin treatment.1

It is a 50 mg tablet and is also in combination with 850 mg or 1 gm of metformin. Metformin is the first choice. If contraindicated then consider Vildagliptin, a sulphonylurea or pioglitazone.

Vildagliptin:

  • is not associated with weight gain
  • has a low risk of hypoglycaemia
  • is not recommended in pregnancy or breastfeeding
  • is associated with a small increased risk of pancreatitis (0.13%)
  • should not be started, and should be withdrawn if persisting levels of AST or ALT greater than 3x upper limit of normal
  • is dosed twice daily but if eGFR < 50 ml/min/1.73m2 reduce to once daily
  • side effects are mild – discontinuation rates ≤ 5%
  • is not recommended in severe CHF (NYHA class IV).

This Gem has been checked by Dr Linda Bryant, Clinical Pharmacist.

Reference:

  1. Vildagliptin – a new treatment for type 2 diabetes. BPAC 2018.  Click here 

Gems are chosen by the Goodfellow director Dr. Bruce Arroll to be either practice changing or practice maintaining. The information is educational and not clinical advice.



As published in NZ Doctor 07/11/2018